Robert L. Ferris
罗伯特·费里斯
MD, PhD
Director, UPMC Hillman Cancer CenterUPMC希尔曼癌症中心主任
👥Biography 个人简介
Robert Ferris is a globally recognized leader in head and neck surgical oncology and tumor immunology. He has pioneered research into immune evasion mechanisms in HNSCC and led pivotal clinical trials of checkpoint inhibitors, including nivolumab for recurrent/metastatic head and neck cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Checkpoint Immunotherapy
Led CheckMate 141 trial establishing nivolumab as standard second-line therapy for recurrent/metastatic HNSCC, changing global practice.
Tumor Immunology
Elucidated mechanisms by which HNSCC evades T-cell immunity, providing rationale for combining immunotherapy with cetuximab.
Representative Works 代表性著作
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
New England Journal of Medicine (2016)
CheckMate 141 trial demonstrating OS benefit of nivolumab over standard therapy in platinum-refractory HNSCC.
Cetuximab and Radiotherapy versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer
New England Journal of Medicine (2019)
NRG/RTOG comparative trial informing standard-of-care decisions in LA-HNSCC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
David J. Adelstein
Cleveland Clinic Taussig Cancer Institute
Maura L. Gillison
MD Anderson Cancer Center
Kevin J. Harrington
Royal Marsden NHS Foundation Trust / Institute of Cancer Research
Jean-Louis Lefebvre
Centre Oscar Lambret
关注 罗伯特·费里斯 的研究动态
Follow Robert L. Ferris's research updates
留下邮箱，当我们发布与 Robert L. Ferris（University of Pittsburgh Medical Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment